依依股份(001206.SZ):擬斥3000萬元-5000萬元回購公司股份
格隆匯8月25日丨依依股份(001206.SZ)公佈,公司擬使用自有資金以集中競價交易方式回購公司發行的人民幣普通股(A股)用於股權激勵或員工持股計劃。本次回購資金總額上限為5000萬元(含),回購資金總額下限為3000萬元(含)。回購股份的價格為不超過人民幣22.00元/股,若按照回購股份價格上限22.00元/股測算,本次回購股份數量區間為1,363,636股至2,272,727股,佔公司目前總股本比例的區間為0.7375%至1.2292%。具體回購數量以回購期滿或回購完成時實際回購的股份數量為準。回購股份實施期限為自公司股東大會審議通過本次回購股份方案之日起12個月內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.